Actionnariat et activité des initiés pour Emergent BioSolutions Inc. (EBS): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $6.75 |
| Capitalisation | $348M |
| Bourse | NYSE |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $271.5M | $178.3M | $112.2M | $168.0M | $621.3M | $576.3M | $642.6M | $111.7M | $99.5M | $205.4M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Créances | $148.5M | $146.1M | $262.5M | $275.3M | $230.9M | $278.9M | $159.2M | $191.0M | $154.5M | $84.2M |
| Stocks | $74.0M | $142.8M | $205.8M | $222.5M | $307.0M | $344.5M | $350.7M | $328.9M | $311.7M | $343.4M |
| Actifs Courants | $510.2M | $485.4M | $620.8M | $686.2M | $1.20B | $1.27B | $1.21B | $679.5M | $598.7M | $662.5M |
| Immobilisations Corporelles | $376.4M | $407.2M | $510.2M | $567.0M | $675.1M | $828.4M | $837.0M | $399.0M | $270.6M | $205.4M |
| Goodwill | $41.0M | $49.1M | $259.7M | $266.6M | $266.7M | $224.9M | $218.2M | 0 | 0 | 0 |
| Actifs Incorporels | $33.9M | $119.6M | $811.6M | $741.9M | $663.1M | $604.6M | $728.8M | $566.6M | $501.5M | $436.5M |
| Actifs Totaux | $970.1M | $1.07B | $2.23B | $2.33B | $2.88B | $2.96B | $3.17B | $1.82B | $1.39B | $1.32B |
| Dettes Fournisseurs | $34.6M | $41.8M | $80.7M | $94.8M | $136.1M | $128.9M | $103.5M | $112.2M | $60.9M | $55.6M |
| Dette à Court Terme | $20.0M | 0 | $10.1M | $16.4M | $39.5M | $37.4M | $963.1M | $413.7M | $2.7M | 0 |
| Passifs Courants | $105.9M | $100.1M | $200.4M | $216.3M | $384.5M | $374.0M | $1.23B | $651.3M | $162.4M | $132.2M |
| Dette à Long Terme | $248.1M | $13.5M | $784.5M | $798.4M | $850.3M | $809.4M | $448.5M | $446.5M | $663.7M | $572.1M |
| Passifs Totaux | $373.9M | $157.9M | $1.22B | $1.24B | $1.44B | $1.35B | $1.78B | $1.17B | $906.9M | $796.0M |
| Réserves | $254.5M | $337.1M | $367.3M | $421.8M | $726.9M | $950.3M | $738.7M | -$21.8M | -$212.4M | -$159.8M |
| Capitaux Propres | $596.2M | $912.3M | $1.01B | $1.09B | $1.45B | $1.61B | $1.39B | $649.3M | $482.8M | $522.6M |
| Dette Totale | $268.1M | $13.5M | $794.6M | $836.9M | $923.0M | $871.0M | $1.43B | $860.2M | $676.1M | $572.1M |
| Dette Nette | -$3.4M | -$164.8M | $682.4M | $668.9M | $301.7M | $294.7M | $783.8M | $748.5M | $576.6M | $366.7M |
| Fonds de Roulement | $404.4M | $385.3M | $420.4M | $469.9M | $811.4M | $895.9M | -$18.5M | $28.2M | $436.3M | $530.3M |
Santé financière
| Dette / Capitaux propres | 1.70 |
| Ratio de liquidité | 5.42 |
Rentabilité
| Rentabilité des capitaux propres | -35.91% |
| Rentabilité du capital investi | -5.47% |
| Rentabilité des actifs | -15.83% |
| Marge brute | 49.40% |
| Marge opérationnelle | -7.06% |
| Marge nette | -22.96% |
Entreprises liées: AQST · CMPS · CRVS · ESPR · OLMA · ORGO · PRTA
Explorer le secteur: Healthcare · Drug Manufacturers - Specialty & Generic
Plus de sections de EBS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions